$910 Million is the total value of Casdin Capital, LLC's 29 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVTA | Sell | INVITAE CORP | $51,524,000 | +94.1% | 2,200,000 | -8.3% | 5.66% | +24.6% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $23,858,000 | +28.7% | 3,365,000 | -11.8% | 2.62% | -17.4% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $22,592,000 | +10.1% | 335,000 | -24.7% | 2.48% | -29.3% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $15,879,000 | +10.5% | 300,000 | -14.3% | 1.74% | -29.0% |
| NTGN | Exit | NEON THERAPEUTICS INC | $0 | – | -263,344 | -100.0% | -0.23% | – |
| QTNT | Exit | QUOTIENT LTD | $0 | – | -325,000 | -100.0% | -0.34% | – |
| IBB | Exit | ISHARES TRnasdaq biotech | $0 | – | -60,000 | -100.0% | -0.99% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -360,000 | -100.0% | -8.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 35 | Q2 2024 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 35 | Q2 2024 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| FATE THERAPEUTICS INC | 27 | Q4 2023 | 8.3% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| BIOLIFE SOLUTIONS INC | 25 | Q2 2024 | 14.9% |
| CODEXIS INC | 25 | Q2 2024 | 8.1% |
| SAREPTA THERAPEUTICS INC | 24 | Q2 2024 | 13.6% |
| ILLUMINA INC | 24 | Q2 2024 | 6.0% |
| DENALI THERAPEUTICS INC | 23 | Q2 2024 | 3.7% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Century Therapeutics, Inc. | April 18, 2024 | 5,190,506 | 6.1% |
| MAXCYTE, INC.Sold out | February 14, 2024 | 0 | 0.0% |
| Relay Therapeutics, Inc. | February 14, 2024 | 7,387,943 | 6.0% |
| EQRx, Inc.Sold out | November 15, 2023 | 0 | 0.0% |
| BIOLIFE SOLUTIONS INC | October 24, 2023 | 8,707,165 | 19.5% |
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-29 |
| 4 | 2024-08-26 |
| 4 | 2024-08-21 |
| 4 | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| SC 13D/A | 2024-08-14 |
| 4 | 2024-08-13 |
| 4 | 2024-08-09 |
| 4 | 2024-08-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.